On February 19, 2025, Petros Pharmaceuticals closed a public offering, selling approximately 13.95 million units and 26.05 million pre-funded units, raising about $9.6 million for working capital. Additionally, stock awards were granted to certain directors and officers totaling 2.1 million shares to incentivize them in connection with the offering.